ID   XDH_HUMAN               Reviewed;        1333 AA.
AC   P47989; Q16681; Q16712; Q4PJ16;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   10-MAY-2017, entry version 179.
DE   RecName: Full=Xanthine dehydrogenase/oxidase;
DE   Includes:
DE     RecName: Full=Xanthine dehydrogenase;
DE              Short=XD;
DE              EC=1.17.1.4 {ECO:0000269|PubMed:8670112};
DE   Includes:
DE     RecName: Full=Xanthine oxidase;
DE              Short=XO;
DE              EC=1.17.3.2 {ECO:0000269|PubMed:17301077, ECO:0000269|PubMed:8670112};
DE     AltName: Full=Xanthine oxidoreductase;
DE              Short=XOR;
GN   Name=XDH; Synonyms=XDHA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=8224915; DOI=10.1016/0378-1119(93)90652-J;
RA   Ichida K., Amaya Y., Noda K., Minoshima S., Hosoya T., Sakai O.,
RA   Shimizu N., Nishino T.;
RT   "Cloning of the cDNA encoding human xanthine dehydrogenase (oxidase):
RT   structural analysis of the protein and chromosomal location of the
RT   gene.";
RL   Gene 133:279-284(1993).
RN   [2]
RP   SEQUENCE REVISION TO 191; 231 AND 1150.
RA   Ichida K.;
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-172.
RC   TISSUE=Liver;
RX   PubMed=8135849; DOI=10.1006/bbrc.1994.1328;
RA   Xu P., Huecksteadt T.P., Harrison R., Hoidal J.R.;
RT   "Molecular cloning, tissue expression of human xanthine
RT   dehydrogenase.";
RL   Biochem. Biophys. Res. Commun. 199:998-1004(1994).
RN   [4]
RP   ERRATUM.
RX   PubMed=7575623; DOI=10.1006/bbrc.1995.2482;
RA   Xu P., Huecksteadt T.P., Harrison R., Hoidal J.R.;
RL   Biochem. Biophys. Res. Commun. 215:429-429(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CATALYTIC ACTIVITY.
RC   TISSUE=Small intestine;
RX   PubMed=8670112; DOI=10.1042/bj3150235;
RA   Saksela M., Raivio K.O.;
RT   "Cloning and expression in vitro of human xanthine
RT   dehydrogenase/oxidase.";
RL   Biochem. J. 315:235-239(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYS-133; ARG-172;
RP   MET-235; MET-395; SER-555; ALA-584; GLN-607; ASN-617; ILE-623;
RP   VAL-646; VAL-703; MET-910; LEU-1091; THR-1109; CYS-1176 AND TRP-1296.
RG   NIEHS SNPs program;
RL   Submitted (JUN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   INVOLVEMENT IN XAN1, AND VARIANT ARG-1150.
RX   PubMed=9153281; DOI=10.1172/JCI119421;
RA   Ichida K., Amaya Y., Kamatani N., Nishino T., Hosoya T., Sakai O.;
RT   "Identification of two mutations in human xanthine dehydrogenase gene
RT   responsible for classical type I xanthinuria.";
RL   J. Clin. Invest. 99:2391-2397(1997).
RN   [8]
RP   INVOLVEMENT IN XAN1.
RX   PubMed=10844591; DOI=10.1046/j.1523-1755.2000.00082.x;
RA   Levartovsky D., Lagziel A., Sperling O., Liberman U., Yaron M.,
RA   Hosoya T., Ichida K., Peretz H.;
RT   "XDH gene mutation is the underlying cause of classical xanthinuria: a
RT   second report.";
RL   Kidney Int. 57:2215-2220(2000).
RN   [9]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-1074.
RC   TISSUE=Milk;
RX   PubMed=18780401; DOI=10.1002/pmic.200701057;
RA   Picariello G., Ferranti P., Mamone G., Roepstorff P., Addeo F.;
RT   "Identification of N-linked glycoproteins in human milk by hydrophilic
RT   interaction liquid chromatography and mass spectrometry.";
RL   Proteomics 8:3833-3847(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF MUTANT VAL-803 IN COMPLEX
RP   WITH FAD; 2FE-2S IRON-SULFUR CENTERS; SALICYLATE; MOLYBDOPTERIN AND
RP   CALCIUM IONS, COFACTOR, CATALYTIC ACTIVITY, FUNCTION, AND SUBUNIT.
RX   PubMed=17301077; DOI=10.1093/jb/mvm053;
RA   Yamaguchi Y., Matsumura T., Ichida K., Okamoto K., Nishino T.;
RT   "Human xanthine oxidase changes its substrate specificity to aldehyde
RT   oxidase type upon mutation of amino acid residues in the active site:
RT   roles of active site residues in binding and activation of purine
RT   substrate.";
RL   J. Biochem. 141:513-524(2007).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (3.59 ANGSTROMS) IN COMPLEX WITH FAD AND
RP   IRON-SULFUR CENTERS, TISSUE SPECIFICITY, ENZYME REGULATION, AND
RP   DISULFIDE BONDS.
RA   Pearson A.R., Godber B.L.J., Eisenthal R., Taylor G.L., Harrison R.;
RT   "Human milk xanthine dehydrogenase is incompletely converted to the
RT   oxidase form in the absence of proteolysis. A structural
RT   explanation.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [13]
RP   VARIANT XAN1 CYS-149.
RX   PubMed=11379872; DOI=10.1007/s004390100477;
RA   Sakamoto N., Yamamoto T., Moriwaki Y., Teranishi T., Toyoda M.,
RA   Onishi Y., Kuroda S., Sakaguchi K., Fujisawa T., Maeda M., Hada T.;
RT   "Identification of a new point mutation in the human xanthine
RT   dehydrogenase gene responsible for a case of classical type I
RT   xanthinuria.";
RL   Hum. Genet. 108:279-283(2001).
RN   [14]
RP   INVOLVEMENT IN XAN1.
RX   PubMed=14551354; DOI=10.1093/ndt/gfg385;
RA   Gok F., Ichida K., Topaloglu R.;
RT   "Mutational analysis of the xanthine dehydrogenase gene in a Turkish
RT   family with autosomal recessive classical xanthinuria.";
RL   Nephrol. Dial. Transplant. 18:2278-2283(2003).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] PHE-763 AND GLY-791.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Key enzyme in purine degradation. Catalyzes the
CC       oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of
CC       xanthine to uric acid. Contributes to the generation of reactive
CC       oxygen species. Has also low oxidase activity towards aldehydes
CC       (in vitro). {ECO:0000269|PubMed:17301077}.
CC   -!- CATALYTIC ACTIVITY: Xanthine + NAD(+) + H(2)O = urate + NADH.
CC       {ECO:0000269|PubMed:8670112}.
CC   -!- CATALYTIC ACTIVITY: Hypoxanthine + NAD(+) + H(2)O = xanthine +
CC       NADH. {ECO:0000269|PubMed:8670112}.
CC   -!- CATALYTIC ACTIVITY: Xanthine + H(2)O + O(2) = urate + H(2)O(2).
CC       {ECO:0000269|PubMed:17301077, ECO:0000269|PubMed:8670112}.
CC   -!- COFACTOR:
CC       Name=[2Fe-2S] cluster; Xref=ChEBI:CHEBI:49601;
CC         Evidence={ECO:0000269|PubMed:17301077};
CC       Note=Binds 2 [2Fe-2S] clusters. {ECO:0000269|PubMed:17301077};
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC         Evidence={ECO:0000269|PubMed:17301077};
CC   -!- COFACTOR:
CC       Name=Mo-molybdopterin; Xref=ChEBI:CHEBI:71302;
CC         Evidence={ECO:0000269|PubMed:17301077};
CC       Note=Binds 1 Mo-molybdopterin (Mo-MPT) cofactor per subunit.
CC       {ECO:0000269|PubMed:17301077};
CC   -!- ENZYME REGULATION: Can be converted from the dehydrogenase form
CC       (D) to the oxidase form (O) irreversibly by proteolysis or
CC       reversibly through the oxidation of sulfhydryl groups.
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Homodimer. Interacts with BTN1A1 (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Peroxisome
CC       {ECO:0000250}. Secreted.
CC   -!- TISSUE SPECIFICITY: Detected in milk (at protein level).
CC       {ECO:0000269|Ref.12}.
CC   -!- PTM: Subject to partial proteolysis; this alters the enzyme from
CC       the dehydrogenase form (D) to the oxidase form (O). {ECO:0000250}.
CC   -!- PTM: Contains sulfhydryl groups that are easily oxidized (in
CC       vitro); this alters the enzyme from the dehydrogenase form (D) to
CC       the oxidase form (O). {ECO:0000250}.
CC   -!- DISEASE: Xanthinuria 1 (XAN1) [MIM:278300]: A disorder
CC       characterized by excretion of very large amounts of xanthine in
CC       the urine and a tendency to form xanthine stones. Uric acid is
CC       strikingly diminished in serum and urine. XAN1 is due to isolated
CC       xanthine dehydrogenase deficiency. Patients can metabolize
CC       allopurinol. {ECO:0000269|PubMed:10844591,
CC       ECO:0000269|PubMed:11379872, ECO:0000269|PubMed:14551354,
CC       ECO:0000269|PubMed:9153281}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the xanthine dehydrogenase family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/xdh/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D11456; BAA02013.2; -; mRNA.
DR   EMBL; U06117; AAA75287.1; -; mRNA.
DR   EMBL; U39487; AAB08399.1; -; mRNA.
DR   EMBL; DQ089481; AAY68219.1; -; Genomic_DNA.
DR   CCDS; CCDS1775.1; -.
DR   PIR; S66573; XOHUDH.
DR   RefSeq; NP_000370.2; NM_000379.3.
DR   UniGene; Hs.250; -.
DR   PDB; 2CKJ; X-ray; 3.59 A; A/B/C/D=2-1333.
DR   PDB; 2E1Q; X-ray; 2.60 A; A/B/C/D=1-1333.
DR   PDBsum; 2CKJ; -.
DR   PDBsum; 2E1Q; -.
DR   ProteinModelPortal; P47989; -.
DR   SMR; P47989; -.
DR   BioGrid; 113335; 3.
DR   IntAct; P47989; 3.
DR   STRING; 9606.ENSP00000368727; -.
DR   BindingDB; P47989; -.
DR   ChEMBL; CHEMBL1929; -.
DR   DrugBank; DB00041; Aldesleukin.
DR   DrugBank; DB00437; Allopurinol.
DR   DrugBank; DB00993; Azathioprine.
DR   DrugBank; DB00958; Carboplatin.
DR   DrugBank; DB01136; Carvedilol.
DR   DrugBank; DB00856; Chlorphenesin.
DR   DrugBank; DB00515; Cisplatin.
DR   DrugBank; DB00694; Daunorubicin.
DR   DrugBank; DB00746; Deferoxamine.
DR   DrugBank; DB03328; dioxothiomolybdenum(VI) ion.
DR   DrugBank; DB00997; Doxorubicin.
DR   DrugBank; DB03516; Eniluracil.
DR   DrugBank; DB04854; Febuxostat.
DR   DrugBank; DB03147; Flavin adenine dinucleotide.
DR   DrugBank; DB04335; Inosine.
DR   DrugBank; DB00583; L-Carnitine.
DR   DrugBank; DB00170; Menadione.
DR   DrugBank; DB01033; Mercaptopurine.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB00336; Nitrofural.
DR   DrugBank; DB05262; Oxypurinol.
DR   DrugBank; DB01168; Procarbazine.
DR   DrugBank; DB00339; Pyrazinamide.
DR   DrugBank; DB00127; Spermine.
DR   DrugBank; DB00831; Trifluoperazine.
DR   DrugBank; DB03841; Y-700.
DR   GuidetoPHARMACOLOGY; 2646; -.
DR   iPTMnet; P47989; -.
DR   PhosphoSitePlus; P47989; -.
DR   BioMuta; XDH; -.
DR   DMDM; 2506326; -.
DR   EPD; P47989; -.
DR   MaxQB; P47989; -.
DR   PaxDb; P47989; -.
DR   PeptideAtlas; P47989; -.
DR   PRIDE; P47989; -.
DR   DNASU; 7498; -.
DR   Ensembl; ENST00000379416; ENSP00000368727; ENSG00000158125.
DR   GeneID; 7498; -.
DR   KEGG; hsa:7498; -.
DR   UCSC; uc002rnv.2; human.
DR   CTD; 7498; -.
DR   DisGeNET; 7498; -.
DR   GeneCards; XDH; -.
DR   H-InvDB; HIX0117690; -.
DR   HGNC; HGNC:12805; XDH.
DR   HPA; HPA062641; -.
DR   HPA; HPA069323; -.
DR   MalaCards; XDH; -.
DR   MIM; 278300; phenotype.
DR   MIM; 607633; gene.
DR   neXtProt; NX_P47989; -.
DR   OpenTargets; ENSG00000158125; -.
DR   Orphanet; 93601; Xanthinuria type I.
DR   PharmGKB; PA37404; -.
DR   eggNOG; KOG0430; Eukaryota.
DR   eggNOG; COG4630; LUCA.
DR   eggNOG; COG4631; LUCA.
DR   GeneTree; ENSGT00390000003772; -.
DR   HOGENOM; HOG000191197; -.
DR   HOVERGEN; HBG004182; -.
DR   InParanoid; P47989; -.
DR   KO; K00106; -.
DR   OMA; LAQADHT; -.
DR   OrthoDB; EOG091G01AW; -.
DR   PhylomeDB; P47989; -.
DR   TreeFam; TF353036; -.
DR   BioCyc; MetaCyc:HS08270-MONOMER; -.
DR   BRENDA; 1.17.1.4; 2681.
DR   Reactome; R-HSA-74259; Purine catabolism.
DR   Reactome; R-HSA-8851680; Butyrophilin (BTN) family interactions.
DR   SABIO-RK; P47989; -.
DR   ChiTaRS; XDH; human.
DR   EvolutionaryTrace; P47989; -.
DR   GeneWiki; Xanthine_dehydrogenase; -.
DR   GenomeRNAi; 7498; -.
DR   PRO; PR:P47989; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000158125; -.
DR   CleanEx; HS_XDH; -.
DR   Genevisible; P47989; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005777; C:peroxisome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016529; C:sarcoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0051537; F:2 iron, 2 sulfur cluster binding; IDA:UniProtKB.
DR   GO; GO:0009055; F:electron carrier activity; IEA:InterPro.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; IDA:UniProtKB.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0043546; F:molybdopterin cofactor binding; IDA:UniProtKB.
DR   GO; GO:0016614; F:oxidoreductase activity, acting on CH-OH group of donors; IEA:InterPro.
DR   GO; GO:0016903; F:oxidoreductase activity, acting on the aldehyde or oxo group of donors; IBA:GO_Central.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0004854; F:xanthine dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0004855; F:xanthine oxidase activity; IDA:UniProtKB.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0007595; P:lactation; IEA:Ensembl.
DR   GO; GO:0045602; P:negative regulation of endothelial cell differentiation; IDA:UniProtKB.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:1900747; P:negative regulation of vascular endothelial growth factor signaling pathway; IDA:UniProtKB.
DR   GO; GO:2001213; P:negative regulation of vasculogenesis; IDA:UniProtKB.
DR   GO; GO:1900745; P:positive regulation of p38MAPK cascade; IDA:UniProtKB.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IDA:UniProtKB.
DR   GO; GO:0006195; P:purine nucleotide catabolic process; TAS:Reactome.
DR   GO; GO:0009115; P:xanthine catabolic process; IDA:UniProtKB.
DR   Gene3D; 1.10.150.120; -; 1.
DR   Gene3D; 3.10.20.30; -; 1.
DR   Gene3D; 3.30.365.10; -; 4.
DR   Gene3D; 3.30.43.10; -; 1.
DR   Gene3D; 3.30.465.10; -; 1.
DR   Gene3D; 3.90.1170.50; -; 1.
DR   InterPro; IPR002888; 2Fe-2S-bd.
DR   InterPro; IPR001041; 2Fe-2S_ferredoxin-type.
DR   InterPro; IPR006058; 2Fe2S_fd_BS.
DR   InterPro; IPR000674; Ald_Oxase/Xan_DH_a/b.
DR   InterPro; IPR016208; Ald_Oxase/xanthine_DH.
DR   InterPro; IPR008274; AldOxase/xan_DH_Mopterin-bd.
DR   InterPro; IPR012675; Beta-grasp_dom.
DR   InterPro; IPR005107; CO_DH_flav_C.
DR   InterPro; IPR016169; CO_DH_flavot_FAD-bd_sub2.
DR   InterPro; IPR016166; FAD-bd_2.
DR   InterPro; IPR016167; FAD-bd_2_sub1.
DR   InterPro; IPR002346; Mopterin_DH_FAD-bd.
DR   InterPro; IPR022407; OxRdtase_Mopterin_BS.
DR   InterPro; IPR014307; Xanthine_DH_ssu.
DR   Pfam; PF01315; Ald_Xan_dh_C; 1.
DR   Pfam; PF02738; Ald_Xan_dh_C2; 1.
DR   Pfam; PF03450; CO_deh_flav_C; 1.
DR   Pfam; PF00941; FAD_binding_5; 1.
DR   Pfam; PF00111; Fer2; 1.
DR   Pfam; PF01799; Fer2_2; 1.
DR   PIRSF; PIRSF000127; Xanthine_DH; 1.
DR   SMART; SM01008; Ald_Xan_dh_C; 1.
DR   SMART; SM01092; CO_deh_flav_C; 1.
DR   SUPFAM; SSF47741; SSF47741; 1.
DR   SUPFAM; SSF54292; SSF54292; 1.
DR   SUPFAM; SSF54665; SSF54665; 1.
DR   SUPFAM; SSF55447; SSF55447; 1.
DR   SUPFAM; SSF56003; SSF56003; 1.
DR   SUPFAM; SSF56176; SSF56176; 1.
DR   TIGRFAMs; TIGR02963; xanthine_xdhA; 1.
DR   PROSITE; PS00197; 2FE2S_FER_1; 1.
DR   PROSITE; PS51085; 2FE2S_FER_2; 1.
DR   PROSITE; PS51387; FAD_PCMH; 1.
DR   PROSITE; PS00559; MOLYBDOPTERIN_EUK; 1.
PE   1: Evidence at protein level;
KW   2Fe-2S; 3D-structure; Complete proteome; Cytoplasm; Disease mutation;
KW   Disulfide bond; FAD; Flavoprotein; Glycoprotein; Iron; Iron-sulfur;
KW   Metal-binding; Molybdenum; NAD; Oxidoreductase; Peroxisome;
KW   Polymorphism; Reference proteome; Secreted.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P80457}.
FT   CHAIN         2   1333       Xanthine dehydrogenase/oxidase.
FT                                /FTId=PRO_0000166084.
FT   DOMAIN        4     91       2Fe-2S ferredoxin-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00465}.
FT   DOMAIN      229    414       FAD-binding PCMH-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00718}.
FT   NP_BIND     257    264       FAD. {ECO:0000269|PubMed:17301077,
FT                                ECO:0000269|Ref.12}.
FT   NP_BIND     347    351       FAD. {ECO:0000269|PubMed:17301077,
FT                                ECO:0000269|Ref.12}.
FT   ACT_SITE   1262   1262       Proton acceptor.
FT   METAL        43     43       Iron-sulfur (2Fe-2S) 1.
FT   METAL        48     48       Iron-sulfur (2Fe-2S) 1.
FT   METAL        51     51       Iron-sulfur (2Fe-2S) 1.
FT   METAL        73     73       Iron-sulfur (2Fe-2S) 1.
FT   METAL       113    113       Iron-sulfur (2Fe-2S) 2.
FT   METAL       116    116       Iron-sulfur (2Fe-2S) 2.
FT   METAL       148    148       Iron-sulfur (2Fe-2S) 2.
FT   METAL       150    150       Iron-sulfur (2Fe-2S) 2.
FT   METAL       768    768       Molybdenum.
FT   METAL       799    799       Molybdenum; via carbonyl oxygen.
FT   METAL       913    913       Molybdenum; via amide nitrogen.
FT   METAL      1080   1080       Molybdenum; via amide nitrogen.
FT   BINDING     337    337       FAD. {ECO:0000269|PubMed:17301077,
FT                                ECO:0000269|Ref.12}.
FT   BINDING     360    360       FAD. {ECO:0000269|PubMed:17301077,
FT                                ECO:0000269|Ref.12}.
FT   BINDING     404    404       FAD; via amide nitrogen and carbonyl
FT                                oxygen. {ECO:0000250}.
FT   BINDING     422    422       FAD. {ECO:0000269|PubMed:17301077,
FT                                ECO:0000269|Ref.12}.
FT   BINDING     803    803       Substrate. {ECO:0000250}.
FT   BINDING     881    881       Substrate.
FT   BINDING     915    915       Substrate. {ECO:0000250}.
FT   BINDING    1011   1011       Substrate.
FT   CARBOHYD   1074   1074       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:18780401}.
FT   DISULFID    509   1318       In oxidase form. {ECO:0000269|Ref.12}.
FT   DISULFID    536    993       In oxidase form. {ECO:0000269|Ref.12}.
FT   VARIANT     133    133       E -> K (in dbSNP:rs45447191).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_023976.
FT   VARIANT     149    149       R -> C (in XAN1; dbSNP:rs72549369).
FT                                {ECO:0000269|PubMed:11379872}.
FT                                /FTId=VAR_045900.
FT   VARIANT     172    172       G -> R (in dbSNP:rs45523133).
FT                                {ECO:0000269|PubMed:8135849,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_023977.
FT   VARIANT     235    235       T -> M (in dbSNP:rs45469499).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_023978.
FT   VARIANT     395    395       K -> M (in dbSNP:rs34929837).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_023979.
FT   VARIANT     555    555       P -> S (in dbSNP:rs45577338).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_023980.
FT   VARIANT     584    584       D -> A (in dbSNP:rs45491693).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_023981.
FT   VARIANT     607    607       R -> Q (in dbSNP:rs45442092).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_023982.
FT   VARIANT     617    617       K -> N (in dbSNP:rs45442398).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_023983.
FT   VARIANT     623    623       T -> I (in dbSNP:rs45448694).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_023984.
FT   VARIANT     646    646       I -> V (in dbSNP:rs17323225).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_023985.
FT   VARIANT     703    703       I -> V (in dbSNP:rs17011368).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_023986.
FT   VARIANT     763    763       L -> F (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035899.
FT   VARIANT     791    791       R -> G (in a breast cancer sample;
FT                                somatic mutation; dbSNP:rs775646772).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035900.
FT   VARIANT     910    910       T -> M (in dbSNP:rs669884).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_023987.
FT   VARIANT    1091   1091       V -> L (in dbSNP:rs45619033).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_023988.
FT   VARIANT    1109   1109       N -> T (in dbSNP:rs45547640).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_023989.
FT   VARIANT    1150   1150       P -> R (in dbSNP:rs1042036).
FT                                {ECO:0000269|PubMed:9153281}.
FT                                /FTId=VAR_045901.
FT   VARIANT    1176   1176       R -> C (in dbSNP:rs45624433).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_023990.
FT   VARIANT    1296   1296       R -> W (in dbSNP:rs45564939).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_023991.
FT   MUTAGEN     803    803       E->V: Strongly decreased activity towards
FT                                xanthine and hypoxanthine. Increased
FT                                affinity and activity towards aromatic
FT                                aldehydes.
FT   MUTAGEN     881    881       R->M: Abolishes xanthine oxidase
FT                                activity.
FT   CONFLICT    259    259       V -> E (in Ref. 3; AAA75287).
FT                                {ECO:0000305}.
FT   CONFLICT    333    334       QL -> HV (in Ref. 3; AAA75287).
FT                                {ECO:0000305}.
FT   CONFLICT    495    495       H -> Q (in Ref. 3; AAA75287).
FT                                {ECO:0000305}.
FT   CONFLICT    515    517       FFF -> LLL (in Ref. 3; AAA75287).
FT                                {ECO:0000305}.
FT   STRAND        6     10       {ECO:0000244|PDB:2E1Q}.
FT   STRAND       13     17       {ECO:0000244|PDB:2E1Q}.
FT   HELIX        26     32       {ECO:0000244|PDB:2E1Q}.
FT   STRAND       44     48       {ECO:0000244|PDB:2E1Q}.
FT   STRAND       52     59       {ECO:0000244|PDB:2E1Q}.
FT   TURN         60     63       {ECO:0000244|PDB:2E1Q}.
FT   STRAND       64     71       {ECO:0000244|PDB:2E1Q}.
FT   TURN         72     74       {ECO:0000244|PDB:2E1Q}.
FT   HELIX        77     79       {ECO:0000244|PDB:2E1Q}.
FT   STRAND       84     86       {ECO:0000244|PDB:2E1Q}.
FT   HELIX        88     90       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       100    107       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       117    130       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       136    141       {ECO:0000244|PDB:2E1Q}.
FT   TURN        142    145       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      149    151       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       154    160       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       161    163       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       198    200       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       206    208       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       214    218       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      227    230       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      235    238       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       242    251       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       264    270       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      276    280       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       285    288       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      290    292       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      294    300       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       305    318       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       321    323       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       325    335       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       340    345       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       348    354       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       362    367       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      371    375       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      380    384       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       387    389       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      403    410       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      416    423       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      425    429       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      433    442       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      448    465       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       467    471       {ECO:0000244|PDB:2E1Q}.
FT   TURN        472    475       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      477    479       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       480    493       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       505    529       {ECO:0000244|PDB:2E1Q}.
FT   TURN        541    543       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       544    547       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      556    560       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       583    587       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       594    596       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      604    610       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      612    622       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       626    628       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      632    637       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       638    640       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      645    648       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      653    656       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      659    661       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      667    675       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       676    684       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      687    692       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       699    705       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      708    718       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       720    726       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      728    737       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      749    754       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      761    765       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       770    781       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       785    787       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      788    793       {ECO:0000244|PDB:2E1Q}.
FT   TURN        799    802       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       807    820       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      824    827       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       830    837       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      843    851       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      857    871       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       875    884       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      893    903       {ECO:0000244|PDB:2E1Q}.
FT   TURN        913    916       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       917    935       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       939    945       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       965    976       {ECO:0000244|PDB:2E1Q}.
FT   HELIX       978    991       {ECO:0000244|PDB:2E1Q}.
FT   STRAND      993   1009       {ECO:0000244|PDB:2E1Q}.
FT   HELIX      1013   1015       {ECO:0000244|PDB:2E1Q}.
FT   STRAND     1017   1024       {ECO:0000244|PDB:2E1Q}.
FT   STRAND     1030   1035       {ECO:0000244|PDB:2E1Q}.
FT   STRAND     1039   1041       {ECO:0000244|PDB:2E1Q}.
FT   HELIX      1043   1055       {ECO:0000244|PDB:2E1Q}.
FT   HELIX      1059   1061       {ECO:0000244|PDB:2E1Q}.
FT   TURN       1069   1071       {ECO:0000244|PDB:2E1Q}.
FT   HELIX      1083   1108       {ECO:0000244|PDB:2E1Q}.
FT   HELIX      1114   1123       {ECO:0000244|PDB:2E1Q}.
FT   STRAND     1129   1135       {ECO:0000244|PDB:2E1Q}.
FT   TURN       1143   1146       {ECO:0000244|PDB:2E1Q}.
FT   STRAND     1152   1166       {ECO:0000244|PDB:2E1Q}.
FT   TURN       1167   1169       {ECO:0000244|PDB:2E1Q}.
FT   STRAND     1172   1182       {ECO:0000244|PDB:2E1Q}.
FT   HELIX      1189   1208       {ECO:0000244|PDB:2E1Q}.
FT   TURN       1225   1227       {ECO:0000244|PDB:2E1Q}.
FT   HELIX      1233   1235       {ECO:0000244|PDB:2E1Q}.
FT   STRAND     1238   1244       {ECO:0000244|PDB:2E1Q}.
FT   HELIX      1254   1256       {ECO:0000244|PDB:2E1Q}.
FT   HELIX      1263   1268       {ECO:0000244|PDB:2E1Q}.
FT   HELIX      1269   1286       {ECO:0000244|PDB:2E1Q}.
FT   HELIX      1303   1309       {ECO:0000244|PDB:2E1Q}.
FT   HELIX      1315   1317       {ECO:0000244|PDB:2E1Q}.
SQ   SEQUENCE   1333 AA;  146424 MW;  806FF2C7413F84C5 CRC64;
     MTADKLVFFV NGRKVVEKNA DPETTLLAYL RRKLGLSGTK LGCGEGGCGA CTVMLSKYDR
     LQNKIVHFSA NACLAPICSL HHVAVTTVEG IGSTKTRLHP VQERIAKSHG SQCGFCTPGI
     VMSMYTLLRN QPEPTMEEIE NAFQGNLCRC TGYRPILQGF RTFARDGGCC GGDGNNPNCC
     MNQKKDHSVS LSPSLFKPEE FTPLDPTQEP IFPPELLRLK DTPRKQLRFE GERVTWIQAS
     TLKELLDLKA QHPDAKLVVG NTEIGIEMKF KNMLFPMIVC PAWIPELNSV EHGPDGISFG
     AACPLSIVEK TLVDAVAKLP AQKTEVFRGV LEQLRWFAGK QVKSVASVGG NIITASPISD
     LNPVFMASGA KLTLVSRGTR RTVQMDHTFF PGYRKTLLSP EEILLSIEIP YSREGEYFSA
     FKQASRREDD IAKVTSGMRV LFKPGTTEVQ ELALCYGGMA NRTISALKTT QRQLSKLWKE
     ELLQDVCAGL AEELHLPPDA PGGMVDFRCT LTLSFFFKFY LTVLQKLGQE NLEDKCGKLD
     PTFASATLLF QKDPPADVQL FQEVPKGQSE EDMVGRPLPH LAADMQASGE AVYCDDIPRY
     ENELSLRLVT STRAHAKIKS IDTSEAKKVP GFVCFISADD VPGSNITGIC NDETVFAKDK
     VTCVGHIIGA VVADTPEHTQ RAAQGVKITY EELPAIITIE DAIKNNSFYG PELKIEKGDL
     KKGFSEADNV VSGEIYIGGQ EHFYLETHCT IAVPKGEAGE MELFVSTQNT MKTQSFVAKM
     LGVPANRIVV RVKRMGGGFG GKETRSTVVS TAVALAAYKT GRPVRCMLDR DEDMLITGGR
     HPFLARYKVG FMKTGTVVAL EVDHFSNVGN TQDLSQSIME RALFHMDNCY KIPNIRGTGR
     LCKTNLPSNT AFRGFGGPQG MLIAECWMSE VAVTCGMPAE EVRRKNLYKE GDLTHFNQKL
     EGFTLPRCWE ECLASSQYHA RKSEVDKFNK ENCWKKRGLC IIPTKFGISF TVPFLNQAGA
     LLHVYTDGSV LLTHGGTEMG QGLHTKMVQV ASRALKIPTS KIYISETSTN TVPNTSPTAA
     SVSADLNGQA VYAACQTILK RLEPYKKKNP SGSWEDWVTA AYMDTVSLSA TGFYRTPNLG
     YSFETNSGNP FHYFSYGVAC SEVEIDCLTG DHKNLRTDIV MDVGSSLNPA IDIGQVEGAF
     VQGLGLFTLE ELHYSPEGSL HTRGPSTYKI PAFGSIPIEF RVSLLRDCPN KKAIYASKAV
     GEPPLFLAAS IFFAIKDAIR AARAQHTGNN VKELFRLDSP ATPEKIRNAC VDKFTTLCVT
     GVPENCKPWS VRV
//
